Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
PLK4
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "PLK4" in MCE Product Catalog:
Cat. No.: HY-115589
CAS No.: 3040940-49-3
Target:
Research Areas:
YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .
Cat. No.: HY-120279A
CAS No.: 1169211-37-3
Target:
Research Areas:
CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM) .
Cat. No.: HY-180111
Target:
Research Areas:
PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma .
Cat. No.: HY-179103
Target:
Research Areas:
PLK4-IN-5 (compound 5f) is a PLK4 (IC50 = 0.8 nM) inhibitor. PLK4-IN-5 can inhibit MCF-7 cell clone formation, induce cell cycle arrest (S/G2 phase), and apoptosis. PLK4-IN-5 has anti proliferative activity against MCF-7 cells (IC50 = 0.48 μM). PLK4-IN-5 can be used in the research of cancer such as breast cancer .
Cat. No.: HY-149912A
Research Areas:
CZS-241 hydrochloride is an orally active and selective inhibitor of Polo-like Kinase 4 (PLK4) (IC50=2.6 nM). CZS-241 hydrochloride inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 hydrochloride induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 hydrochloride shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .
Cat. No.: HY-15800
CAS No.: 1330003-04-7
Research Areas:
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases .
Cat. No.: HY-162895
NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth .
Cat. No.: HY-116190
CAS No.: 1430741-35-7
Target:
Research Areas:
CFI-401870 is an orally active threonine tyrosine kinase (TTK (Mps1)) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer .
Cat. No.: HY-P703290
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein Kinase; Prev. STK18; Polo-Like Kinase 4 (Drosophila); Serine/Threonine-Protein Kinase PLK4; Serine/Threonine Kinase 18; Polo-Like Kinase 4; Snk Akin Kinase; Sak; MCCRP2; Serine/Threonine-Protein Kinase Sak; PLK-
Species:
Human
Source:
E. coli
Cat. No.: HY-P705861
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein Kinase; Prev. STK18; Polo-Like Kinase 4 (Drosophila); Serine/Threonine-Protein Kinase PLK4; Serine/Threonine Kinase 18; Polo-Like Kinase 4; Snk Akin Kinase; Sak; MCCRP2; Serine/Threonine-Protein Kinase Sak; PLK-
Species:
Human
Source:
E. coli
Cat. No.: HY-P72780
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein Kinase; Prev. STK18; Polo-Like Kinase 4 (Drosophila); Serine/Threonine-Protein Kinase PLK4; Serine/Threonine Kinase 18; Polo-Like Kinase 4; Snk Akin Kinase; Sak; MCCRP2; Serine/Threonine-Protein Kinase Sak; PLK-
Species:
Staphylococcus aureus
Source:
E. coli
Cat. No.: HY-P71923A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein Kinase; Prev. STK18; Polo-Like Kinase 4 (Drosophila); Serine/Threonine-Protein Kinase PLK4; Serine/Threonine Kinase 18; Polo-Like Kinase 4; Snk Akin Kinase; Sak; MCCRP2; Serine/Threonine-Protein Kinase Sak; PLK-
Species:
Others
Source:
E. coli
Cat. No.: HY-187506
Target:
Research Areas:
ZSL-M028 is an orally active and selective Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 1.1 nM. ZSL-M028 exhibits anti-tumor activity against TRIM37-amplified neuroblastoma, downregulates SAS6, upregulates FBXW5, induces G2-phase cell cycle arrest and apoptosis, activates the p53 signaling pathway, and inhibits tumor cell colony formation and migration. ZSL-M028 shows significant tumor growth inhibitory activity in the IMR-32 neuroblastoma xenograft model. ZSL-M028 can be used in neuroblastoma-related research .
Cat. No.: HY-184113
Synonyms: DHP
Target:
Research Areas:
Dihydropelitinib (DHP) is a ILK ligand with a Kd value of 252 nM. Dihydropelitinib acts as a cytoskeleton modulator that induces actin (Actin) cytoskeleton rearrangement. Dihydropelitinib exhibits anticancer activity against liver cancer and lung adenocarcinoma. Dihydropelitinib can be used in studies related to liver cancer and lung adenocarcinoma .
Cat. No.: HY-184652
Target:
Research Areas:
LRRK2/JNK3-IN-1 is a brain-penetrant multi-target inhibitor of LRRK2 (including G2019S mutant and wild-type) and JNK3, with enzymatic IC50 values of 3.90 nM against LRRK2 G2019S, 3.24 nM against wild-type LRRK2, and 22.1 nM against JNK3. LRRK2/JNK3-IN-1 displays favorable selectivity in a 97-kinase profiling screen, and also shows inhibitory activity against JNK1, JNK2, and MKNK2. LRRK2/JNK3-IN-1 can be used for the research of Parkinson's disease .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
